Sven Petto

[89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates

A. Schaefer-Schuler, M. Bartholomä, G. Franssen, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates

A. Schaefer-Schuler, M. Bartholomä, G. Franssen, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

Detection efficacy of [89Zr]Zr-PSMA-617 PET/CT in [68Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer

A. Schaefer-Schuler, M. Bartholomä, S. Maus, 2023, European Journal of Nuclear Medicine and Molecular Imaging.

Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry

A. Schaefer-Schuler, M. Bartholomä, S. Maus, 2023, European journal of nuclear medicine and molecular imaging.

[89Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [68Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis

A. Schaefer-Schuler, M. Bartholomä, R. Marlowe, 2024, Cancer imaging : the official publication of the International Cancer Imaging Society.

225Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy

A. Schaefer-Schuler, M. Bartholomä, F. Rosar, 2024, Clinical nuclear medicine.

Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT

A. Schaefer-Schuler, M. Bartholomä, R. Marlowe, 2024, Scientific reports.